Thromboembolism
Information
- Disease name
- Thromboembolism
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06443905 | Active, not recruiting | Xueshuantong Injection (Lyophilized) in the Prevention of Venous Thromboembolism (VTE) in Hospitalized Patients | August 1, 2023 | December 30, 2024 | |
| NCT05643885 | Active, not recruiting | A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer | August 31, 2022 | June 30, 2024 | |
| NCT05656963 | Active, not recruiting | The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD | September 1, 2021 | January 31, 2024 | |
| NCT05563883 | Active, not recruiting | Atrial Fibrillation and Cancer: a Nationwide French Cohort Study | September 22, 2022 | January 2030 | |
| NCT00020189 | Completed | Phase 2 | Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | June 2000 | August 2004 |
| NCT00024297 | Completed | N/A | Warfarin in Preventing Blood Clots in Cancer Patients With Central Venous Catheters | October 1999 | February 2009 |
| NCT00038961 | Completed | Phase 3 | A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO). | November 2001 | October 2004 |
| NCT00041457 | Completed | Epidemiology of Venous Thromboembolism | July 2002 | June 2006 | |
| NCT00064428 | Completed | Phase 3 | OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction | August 2003 | February 2006 |
| NCT00071032 | Completed | Phase 3 | Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease | July 2003 | May 2009 |
| NCT00094185 | Completed | Clotting Genetic Variants, Hormones, and Venous Thrombosis | May 2004 | March 2009 | |
| NCT00096590 | Completed | Detecting Abnormal Blood Clotting in Patients With Metastatic Cancer Undergoing Surgery | November 2004 | ||
| NCT00139815 | Completed | Phase 3 | Michelangelo - Oasis 5 | April 2003 | December 2005 |
| NCT00152971 | Completed | Phase 3 | Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement | November 2004 | |
| NCT00168805 | Completed | Phase 3 | RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery | November 2004 | |
| NCT00168818 | Completed | Phase 3 | Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery | November 2004 | |
| NCT00203580 | Completed | Phase 4 | Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) | December 1994 | March 2002 |
| NCT00203658 | Completed | Phase 4 | Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin | April 1997 | October 2000 |
| NCT00205400 | Completed | N/A | Comparison of Patient Outcomes Using Different Delivery Models of Anticoagulation Care | August 1999 | |
| NCT00253669 | Completed | Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas | April 2005 | August 2009 | |
| NCT00260988 | Completed | Phase 2/Phase 3 | A Comparison of Dalteparin and Tinzaparin for Prevention of Blood Clots in Hemodialysis Patients on Oral Anticoagulants Having Surgery | October 2003 | November 2008 |
| NCT00266994 | Completed | HTRS TE Registry (ThromboEmbolism Registry) | December 2005 | October 2012 | |
| NCT00291330 | Completed | Phase 3 | Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism | February 2006 | |
| NCT00320424 | Completed | Phase 3 | Hip Fracture Study of GSK576428 (Fondaparinux Sodium) | February 16, 2006 | October 26, 2006 |
| NCT00328939 | Completed | Phase 3 | ARIXTRA Local Study For Registration In China. | May 2004 | |
| NCT00329238 | Completed | Phase 3 | Secondary Prevention of Venous Thrombo Embolism (VTE). | May 2006 | |
| NCT00353678 | Completed | Phase 2 | Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2) | June 2006 | August 2007 |
| NCT00362492 | Completed | Phase 4 | Safety Study of Stopping Thromboprophylaxis Based on Ultrasound Results After Total Knee Replacement | June 2004 | June 2007 |
| NCT00371501 | Completed | Phase 4 | Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus | June 2006 | December 2009 |
| NCT00375609 | Completed | Phase 2 | Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT) | May 2006 | February 2007 |
| NCT00381888 | Completed | Phase 2 | Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer | January 2007 | January 2009 |
| NCT00408239 | Completed | Phase 2 | Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement | December 2006 | March 2009 |
| NCT00433602 | Completed | Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors | November 2006 | ||
| NCT00451412 | Completed | Phase 3 | A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients | January 2007 | June 2009 |
| NCT00462852 | Completed | Phase 2 | Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | April 2003 | November 2011 |
| NCT00486915 | Completed | N/A | Impact of Left Atrial Appendage Exclusion on Short-Term Clinical Outcomes and Long-Term Stroke Incidence | April 2007 | December 2012 |
| NCT00504556 | Completed | Phase 2 | A Study to Assess the Safety of a Potential New Drug in Comparison to the Standard Practice of Dosing With Warfarin for Non-valvular Atrial Fibrillation | June 2007 | June 2008 |
| NCT05162339 | Completed | Inflammatory Bowel Disease and Thromboembolic Events | November 1, 2016 | April 30, 2020 | |
| NCT00004875 | Completed | Heparin or Enoxaparin in Patients With Cancer | July 1996 | March 1999 | |
| NCT00011180 | Completed | Risk Factors for Venous Thromboembolism in the Community | April 2001 | May 2009 | |
| NCT00014352 | Completed | Phase 2 | Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | September 2000 | |
| NCT00839826 | Completed | Phase 2 | ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial | December 2002 | November 2003 |
| NCT00846807 | Completed | Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery | February 2009 | ||
| NCT00847301 | Completed | Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery | April 2009 | July 2014 | |
| NCT00911001 | Completed | SALTO - Epidemiological Study on Compliance and Treatment Satisfaction | November 2008 | March 2009 | |
| NCT00927862 | Completed | Phase 2/Phase 3 | Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin | August 2008 | June 2011 |
| NCT00964275 | Completed | N/A | Standard Diagnostic Procedures With or Without Fludeoxyglucose F 18 Positron Emission Tomography in Finding Cancer in Patients With a Blood Clot in a Vein | March 2009 | October 2014 |
| NCT00986154 | Completed | Phase 3 | Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). | October 2009 | April 2013 |
| NCT01004939 | Completed | Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and/or Postpartum for Prophylaxis or Treatment of Venous Thromboembolism | March 2010 | July 2010 | |
| NCT01006733 | Completed | Phase 3 | Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT | March 2011 | November 2016 |
| NCT01006876 | Completed | Phase 3 | Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation | January 2010 | April 2014 |
| NCT01068795 | Completed | N/A | Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome | July 2009 | August 2015 |
| NCT01094886 | Completed | Phase 3 | Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement | March 2010 | December 2010 |
| NCT01132833 | Completed | Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy | December 2008 | January 2016 | |
| NCT01203098 | Completed | Phase 2 | A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty | July 2008 | June 2009 |
| NCT01420809 | Completed | Special Drug Use Investigation for ARIXTRA® (Fondaparinux) Injection | September 2007 | August 2009 | |
| NCT01452568 | Completed | Phase 4 | Anticoagulant After Implantation of Biological Aortic Valve Comparing With Aspirin | June 2005 | March 2012 |
| NCT01541995 | Completed | Evaluation of Contrast Medium Enhanced Post-mortem CT in Virtual Autopsy | April 2012 | ||
| NCT01565239 | Completed | Phase 2 | Fiix-prothrombin Time for Monitoring Warfarin | March 2012 | February 2014 |
| NCT01696760 | Completed | N/A | Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology | October 2010 | December 2012 |
| NCT01707394 | Completed | Phase 1 | Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic Disorder | January 10, 2013 | June 30, 2020 |
| NCT02064439 | Completed | Phase 3 | Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) | March 5, 2014 | November 4, 2016 |
| NCT02103101 | Completed | N/A | Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events | November 13, 2014 | October 31, 2017 |
| NCT02376803 | Completed | Phase 4 | The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The "INRange" RCT | February 2015 | April 27, 2018 |
| NCT02447081 | Completed | Amplatzer™Amulet™ Post-Market Study (Amulet™PMS) | June 1, 2015 | October 23, 2018 | |
| NCT02564718 | Completed | Phase 1/Phase 2 | Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates | November 19, 2015 | December 18, 2017 |
| NCT02584842 | Completed | Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy | January 2012 | December 2014 | |
| NCT02776566 | Completed | N/A | Patient-Centered Anticoagulation Self-Monitoring in Minority Patients | January 2016 | February 2019 |
| NCT02779400 | Completed | N/A | Assessment of a Diagnostic Medical Device for the INR (International Normalized Ratio) Measurement | May 23, 2016 | June 1, 2018 |
| NCT02864810 | Completed | Phase 1 | Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism | August 4, 2016 | September 9, 2017 |
| NCT02913326 | Completed | Phase 3 | A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT) | December 13, 2016 | June 22, 2018 |
| NCT02935751 | Completed | Apixaban Discontinuation Prior to Major Surgery | October 2016 | September 2018 | |
| NCT02964208 | Completed | AMPLATZER™ LAA Occluder Post Approval Study (PAS) | December 8, 2016 | August 10, 2022 | |
| NCT03359889 | Completed | PraxbindTM India PMS Program | December 26, 2018 | January 13, 2020 | |
| NCT03581877 | Completed | Phase 4 | Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE | January 28, 2019 | March 19, 2023 |
| NCT03854149 | Completed | Apixaban in Adults With Congenital Heart Disease and Atrial Arrhythmias: the PROTECT-AR Study | July 1, 2019 | May 30, 2023 | |
| NCT03877770 | Completed | DVT After Cardiac Procedure | October 20, 2017 | July 31, 2019 | |
| NCT03914053 | Completed | Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine | July 1, 2017 | December 31, 2018 | |
| NCT04072068 | Completed | Phase 4 | Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy | June 27, 2019 | March 8, 2022 |
| NCT04305756 | Completed | N/A | Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery | June 12, 2020 | December 15, 2021 |
| NCT04394000 | Completed | Impact of an Intensified Thromboprofylaxis Protocol in COVID-19 | May 4, 2020 | May 15, 2020 | |
| NCT04499612 | Completed | Influence of Cardiac Implantable Electronic Devices on the Hemostatic System | March 1, 2020 | November 1, 2023 | |
| NCT04593654 | Completed | Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients | March 1, 2020 | October 15, 2020 | |
| NCT04616846 | Completed | N/A | Thromboembolic Risk Screening in Patients With Cancer and COVID-19 | August 4, 2020 | January 25, 2022 |
| NCT04686981 | Completed | Endovascular thromBectomy of Acute Mesentery Vessels Occlusion Hybrid With Emergent Laparoscopic Surgery | October 1, 2020 | July 1, 2023 | |
| NCT04719182 | Completed | Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19 | September 1, 2020 | April 1, 2021 | |
| NCT00000614 | Completed | Phase 3 | Prevention of Recurrent Venous Thromboembolism (PREVENT) | September 1998 | August 2004 |
| NCT05256524 | Completed | Is Anti-Factor Xa Associated With Outcome in Patients With Critical COVID-19 on Low-Molecular-Weight Heparin? | March 1, 2020 | August 29, 2021 | |
| NCT00680186 | Completed | Phase 3 | Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE) | April 2008 | |
| NCT00781378 | Completed | Phase 4 | Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China | June 2002 | February 2006 |
| NCT00794560 | Completed | Phase 4 | Self-management of Low Molecular Weight Heparin Therapy | June 2007 | August 2009 |
| NCT00796692 | Completed | Phase 4 | Nadroparin for the Initial Treatment of Pulmonary Thromboembolism | June 2002 | February 2006 |
| NCT00799968 | Completed | Phase 4 | 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China | June 2002 | February 2006 |
| NCT00830570 | Completed | The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings | July 2007 | January 2010 | |
| NCT05794165 | Enrolling by invitation | Phase 2 | Antithrombin to Improve Thromboprophylaxis and Reduce the Incidence of Trauma-Related Venous Thromboembolism | September 5, 2023 | March 2027 |
| NCT04258488 | Recruiting | Phase 4 | Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement | February 21, 2022 | June 30, 2025 |
| NCT05625932 | Recruiting | Phase 3 | TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer | March 2, 2023 | March 2025 |
| NCT03897478 | Recruiting | Biomarkers of Acute Stroke in Clinic | April 1, 2019 | December 31, 2024 | |
| NCT05575466 | Recruiting | Thromboembolism in Anorexia Nervosa | November 15, 2022 | November 30, 2026 | |
| NCT06065592 | Recruiting | Phase 1 | Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms | February 1, 2019 | December 2024 |
| NCT06442267 | Recruiting | Phase 4 | Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support | June 25, 2024 | November 30, 2026 |
| NCT05178628 | Recruiting | Phase 3 | The Impact of Thromboprophylaxis on Progression Free Survival of Patients With Advanced Pancreatic Cancer | February 10, 2022 | December 31, 2024 |
| NCT06118957 | Recruiting | Phase 2 | Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery | October 11, 2023 | July 1, 2024 |
| NCT04628078 | Recruiting | LAAC-registry: Clinical Outcome After Echocardiography-guided LAA-closure | August 12, 2015 | June 1, 2027 | |
| NCT06062329 | Recruiting | N/A | SYMPHONY-PE Study for Treatment of Pulmonary Embolism | December 8, 2023 | April 2025 |
| NCT05301348 | Recruiting | N/A | In Vivo Detection of Circulating Clots in Patients With Thromboembolism | July 26, 2023 | January 31, 2026 |
| NCT05796557 | Recruiting | Phase 4 | ECMO Hemostatic Transfusions in Children | December 12, 2023 | September 1, 2025 |
| NCT03424330 | Recruiting | N/A | Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence. | January 9, 2019 | December 25, 2023 |
| NCT05313620 | Recruiting | Phase 4 | Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events | April 1, 2022 | October 2024 |
| NCT03659708 | Recruiting | N/A | Pregnancy and Risk of Venous Thromboembolism | January 22, 2021 | October 22, 2026 |
| NCT04997265 | Recruiting | N/A | Strategies for Anticoagulation During Venovenous ECMO | May 12, 2022 | May 12, 2024 |
| NCT03855592 | Recruiting | Registry of Thrombosis & NEoplasia of "Sociedad Española de Oncología Médica" | July 4, 2018 | July 2024 | |
| NCT05548010 | Recruiting | Venous Thromboembolism (VTE) Knowledge | November 29, 2022 | November 29, 2023 | |
| NCT02094157 | Terminated | Phase 3 | Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation | December 2007 | March 2014 |
| NCT00655122 | Terminated | Phase 4 | Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study | April 2003 | December 2003 |
| NCT00662688 | Terminated | Phase 3 | Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic Cancer | October 2007 | December 2012 |
| NCT00031837 | Terminated | Phase 3 | Gemcitabine With or Without Dalteparin in Treating Patients With Unresectable or Metastatic Pancreatic Cancer | October 2002 | December 2006 |
| NCT00967447 | Terminated | Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery | February 2009 | ||
| NCT04199793 | Terminated | N/A | Lavare Cycle in Patients Receiving HeartWare Left Ventricular Assist Device | August 10, 2020 | August 10, 2021 |
| NCT01505881 | Terminated | Phase 2 | Follow on Study From RE-ALIGN | December 2011 | June 2013 |
| NCT00423683 | Terminated | Phase 3 | Anticoagulation and Inferior Vena Cava Filters in Cancer Patients With a Venous Thromboembolism | January 2007 | November 2010 |
| NCT00206089 | Terminated | Phase 3 | Melagatran/Ximelagatran Versus Enoxaparin for the Prevention of Venous Thromboembolic Events | September 2005 | August 2006 |
| NCT02475187 | Terminated | Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture | September 2015 | February 1, 2018 | |
| NCT02579122 | Terminated | REVIparin-BRIDging-in a General Practice Setting in GErmany | October 2015 | July 2016 | |
| NCT00444652 | Unknown status | Phase 4 | Thromboprophylaxis and Bariatric Surgery | November 2006 | December 2012 |
| NCT04301362 | Unknown status | Biomarkers of Thrombosis as Predictors of Venous Thromboembolism Risk in Cancer Patients | July 19, 2019 | December 19, 2021 | |
| NCT02522221 | Unknown status | Phase 3 | Tecarfarin Anti-Coagulation Trial (TACT) | June 1, 2018 | July 1, 2019 |
| NCT04813575 | Unknown status | N/A | COVID-19 Pathophysiology of Long Term Implications | August 1, 2021 | June 1, 2022 |
| NCT00982514 | Unknown status | Thromboembolic Complications Related to Asparaginase in Children With Acute Lymphoblastic Leukemia (ALL) Treated According to NOPHO ALL 2008 | September 2009 | December 2014 | |
| NCT04246073 | Unknown status | Prospective Evaluation of Efficacy and Safety of Fondaparinux in Surgical Cancer Patients, Risk Factors for Thromboembolism | February 1, 2019 | December 1, 2020 | |
| NCT04746521 | Unknown status | Cellular-Mediated Immunity in COVID-19 | March 14, 2021 | December 14, 2022 | |
| NCT00519805 | Unknown status | Phase 3 | Dalteparin in Preventing Blood Clots in Patients With Lung Cancer | August 2007 | |
| NCT03073915 | Unknown status | Evaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments | August 2013 | December 2020 | |
| NCT02295150 | Unknown status | Phase 4 | Prophylaxis of Venous Thromboembolism After Bariatric Surgery | March 2013 | June 2015 |
| NCT02313584 | Unknown status | Phase 3 | Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk | December 2014 | September 2017 |
| NCT03893461 | Unknown status | Coagulation System In STereotactic Radiotherapy Of NSCLC | March 26, 2019 | December 31, 2022 | |
| NCT05067153 | Unknown status | Phase 4 | Thromboprophylaxis in Oesophageal Cancer Patients | May 1, 2021 | May 1, 2024 |
| NCT01319201 | Unknown status | Subclinical Atherosclerosis Using Dual-source CT Coronary Angiography in Chinese Adults With Different Glycaemic Status | April 2010 | ||
| NCT01372514 | Unknown status | Institutional Registry of Thromboembolic Disease | August 2006 | January 2020 | |
| NCT00868179 | Withdrawn | Phase 4 | A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days | April 2009 | April 2012 |
| NCT02970773 | Withdrawn | Phase 4 | Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury | December 4, 2017 | December 7, 2018 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0001907
- MeSH unique ID (MeSH (Medical Subject Headings))
- D013923